Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

IrelandBack to Ireland

Clinical trials in Waterford – page 3

45 clinical trials in Waterford, Ireland across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Waterford at a glance
45
clinical trials
  • Paediatric trials0
  • Research sites1
Type of trial
Recruitment status
Quick filters

45 trials in Waterford

Open in trial search

Breast cancer

Not recruiting

Study on the Effects of Chemotherapy and Endocrine Therapy in Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer Using Tamoxifen and Anastrozole

Registered drugNo placebo
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Cancer Trials Ireland

Plasma cell myeloma

Not recruiting

Study on the Effectiveness and Safety of Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Cancer Trials Ireland

Malignant melanoma

Not recruiting

Study on Fianlimab and Cemiplimab for Adults with Resectable Stage III and IV Melanoma

Registered drug
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Bladder cancer

Not recruiting

Study of Pembrolizumab and Enfortumab Vedotin with Surgery vs. Surgery Alone for Patients with Muscle-Invasive Bladder Cancer Who Cannot or Choose Not to Use Cisplatin

Registered drugNo placebo
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Merck Sharp & Dohme LLC

Autonomic nervous system imbalance+1

Not recruiting

Study on Elinzanetant for Treating Hot Flashes in Women with or at High Risk for Hormone-Receptor Positive Breast Cancer

Investigational
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Elinzanetant
  • Sponsor:Bayer AG

Cervix carcinoma

Not recruiting

Study on Tisotumab Vedotin, Bevacizumab, Carboplatin, and Pembrolizumab for Patients with Recurrent or Stage IVB Cervical Cancer

Registered drugNo placebo
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

Ovarian cancer

Not recruiting

Study on Niraparib for Maintenance Treatment in Patients with Advanced Ovarian Cancer After Initial Chemotherapy Response

Registered drug
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Niraparib Tosilate Monohydrate
  • Sponsor:Tesaro Inc.

Mantle cell lymphoma

Not recruiting

Study of Zanubrutinib and Rituximab Compared to Bendamustine and Rituximab for Patients with Untreated Mantle Cell Lymphoma Ineligible for Stem Cell Transplant

Registered drugNo placebo
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:BeOne Medicines AG

Chronic lymphocytic leukaemia

Not recruiting

Study of pirtobrutinib, venetoclax and rituximab combination compared to venetoclax and rituximab in previously treated Chronic Lymphocytic Leukemia patients

Registered drugNo placebo
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Pirtobrutinib
  • Sponsor:Loxo Oncology Inc.

Gastric cancer+5

Not recruiting

Study on Aspirin's Effect on Recurrence and Survival in Patients with Non-Metastatic Breast, Colon, Rectal, Stomach, Esophageal, and Prostate Cancer

Registered drug
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:University College London

Non-small cell lung cancer

Not recruiting

Study of Pembrolizumab for Patients with Early Stage Non-Small Cell Lung Cancer After Surgery and Standard Therapy

Registered drug
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Breast cancer+1

Not recruiting

Study of ribociclib combined with hormone therapy for patients with early-stage hormone receptor-positive, HER2-negative breast cancer

Registered drugNo placebo
Countries:IrelandIreland
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Novartis Pharma AG

Other cities in Ireland

The busiest research cities in the country

All 16 cities in Ireland

Clinical research in Waterford

What the registry says about research in the country

01 Oncology Research

Groundbreaking clinical trials focusing on multiple myeloma, breast cancer, and various forms of lung cancer are currently underway. Studies are evaluating novel combination therapies and investigating innovative treatment approaches for both early-stage and advanced cancers.

  • Multiple Myeloma Treatment Innovations
  • Breast Cancer Therapeutic Advances
  • Lung Cancer Treatment Strategies

New therapeutic combinations are being tested to improve patient outcomes and survival rates.

02 Hematological Studies

Research into blood disorders focuses on chronic lymphocytic leukemia and lymphoma. Clinical trials are evaluating fixed-duration treatments and combination therapies to enhance treatment effectiveness.

  • CLL Treatment Optimization
  • Lymphoma Therapy Development
  • Novel Drug Combinations

Investigations aim to establish optimal treatment durations and improve patient responses.

03 Ophthalmology Advances

Studies in eye care concentrate on macular degeneration and glaucoma. Research includes innovative treatments for age-related conditions and new approaches to managing ocular pressure.

  • AMD Treatment Solutions
  • Glaucoma Management
  • Vision Preservation Strategies

These trials aim to develop more effective treatments for preserving vision and managing eye conditions.

Back to IrelandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.